The ADC binds HER2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor that causes DNA damage and cell death; Topoisomerase I is the intracellular payload target, not the binding target, so Topoisomerase I–expressing cells alone are not selectively killed unless they are HER2-positive.